Preliminary weight loss and safety data for Structure Therapeutics' drug candidate suggest it's competitive with other oral GLP-1 targeting contenders from big pharma companies. The data are from a small study and a short time frame, but Structure was able to leverage the encouraging preliminary results into a private placement of securities.
Dr. Anil Singh, Senior Vice President and Executive Medical Director with Highmark Health discusses the strategies of finding the best digital solutionsfor their members. He addresses the future of healthcare with the rise of AI and how utilizing that technology can help connect members with their specific needs.
It makes sense that when care navigation prioritizes the patient and better links them to care by reducing barriers and smoothing out the road to seeing a provider, the patient experiences better outcomes. Better outcomes also translates to fewer hospital readmissions, saving money for both patients and their employers.
Right now, manufacturers are thriving. Hospitals are failing. And patients are suffering. We must stop this trend in its tracks by becoming better stewards of hospital resources and supply chains.
Preliminary weight loss and safety data for Structure Therapeutics' drug candidate suggest it's competitive with other oral GLP-1 targeting contenders from big pharma companies. The data are from a small study and a short time frame, but Structure was able to leverage the encouraging preliminary results into a private placement of securities.
Midi Health's Series A funding round was led by Google Ventures. In total, Midi Health has raised $40 million, including from Felicis, Semper Virens, Icon, 25M and Operator Collective. The company offers virtual care for those going through perimenopause or menopause.
For September's guest interview, we were joined by Chris Allen, who recently became CFO at Keck Medicine of USC. Some of his recent past roles include CFO of Adventist Health and senior director of budget and decision support at UC Irvine Health.
No comments:
Post a Comment